{"entity":{"id":"her2","kind":"target","name":"HER2","aka":[],"tldr":"A growth-signal receptor. Some cancers make far too much of it, and drugs that block it or use it as a docking site have transformed those cancers.","summary":"Human epidermal growth factor receptor 2 is a receptor tyrosine kinase amplified in ~15-20% of breast cancers and a subset of gastric, colorectal, lung (mutations), and biliary cancers. Trastuzumab (1998) was the first targeted antibody in solid tumours. Trastuzumab deruxtecan redefined the target by working in 'HER2-low' tumours that older drugs ignored, and in 2026 gained approval in early-stage disease.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/HER2/neu","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/HER2/neu"}],"tags":["adc-target","driver"],"related":["her2-ish-amplified","her2-ihc-3-plus","her2-mutation","her2-ihc-2-plus","her2-ihc-1-plus","her2-ihc-0","her2-low-ihc","her2-ultralow"],"cancers":["breast-her2-positive","breast-hr-positive","gastric","nsclc","colorectal","cholangiocarcinoma","tnbc","pancreatic","gallbladder"],"sections":[],"technologies":["her2-tyrosine-kinase-inhibitors"],"targets":[],"drugs":["her2-testing-assays","tqb2102","kn026","ibi354","a166","hlx22","glsi-100","hlx11","rph-051","ro7771950","ose2101","gq1005","iah0968","tqb2930","ssgj-705","avzo-021","cinrebafusp-alfa","absk061","ssgj-612"],"companies":["dualitybio","amunix-pharmaceuticals","callio-therapeutics","cogent-biosciences","dantari","enliven-therapeutics","ibex-medical-analytics","iksuda-therapeutics","imagene-ai","myricx-bio","orum-therapeutics","precirix"],"institutions":[],"pathways":["pi3k-akt-mtor","ras-mapk","bladder-cancer-signalling","breast-cancer-signalling","endometrial-cancer-signalling","gastric-cancer-signalling","pancreatic-cancer-signalling"],"terms":["her2-low","gene-amplification","her2-testing-in-biliary-cancer"],"trials":["nct06043817","nct07589517","nct05532696","nct07510802","nct05523947","nct06369831","nct07467863","nct06616766","nct06439771","nct05771584","nct07641023","nct07462650","nct07192432"],"people":[],"bottlenecks":[],"keyPapers":["paper-slamon-her2-breast-ovarian-science-1989","paper-yarden-sliwkowski-erbb-network-nrmcb-2001","paper-schettini-her2-low-features-npj-breast-cancer-2021","paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021","paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026","paper-destiny-breast04-nejm-2022","paper-waddell-whole-genomes-pancreatic-nature-2015","paper-philip-kras-wild-type-pancreatic-ccr-2022","paper-tcga-colorectal-comprehensive-characterization-nature-2012","paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016","paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011","paper-seshagiri-rspo-fusions-colon-nature-2012","paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024","paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025","paper-giraldo-gallbladder-msk-impact-ccr-2022","paper-javle-biliary-ngs-cancer-2016","paper-hiraoka-her2-status-biliary-hum-pathol-2020","paper-roa-her2-overexpression-gallbladder-gcr-2014","paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026","paper-harding-lancet-oncol","paper-javle-mypathway-her2-biliary-lancet-oncol-2021","paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024","paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026","paper-kris-lung-cancer-mutation-consortium-jama-2014","paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013"],"journals":[],"dependsOn":[],"notes":["Triple-negative breast cancer, HER2-low and ultralow: HER2-low (IHC 1+ or 2+/ISH-negative) in 36.6% of TNBC among 3,689 HER2-negative patients (Schettini 2021) and 34.0% of 1,162 hormone receptor-negative trial patients (Denkert 2021); HER2-null 38.4%, ultralow 37.6% and low 24.0% of 367 untreated TNBCs (Boissiere-Michot 2026). DESTINY-Breast04 enrolled 63 hormone receptor-negative patients (Modi 2022) and the HER2-low label covers them; DESTINY-Breast06 and the ultralow label are hormone receptor-positive only. In TNBC no gene separates HER2-low from HER2-0 and pathologist agreement is poor (Schettini 2021).","Pancreatic ductal adenocarcinoma: ERBB2 amplification in 1 to 5% by platform and mutation in under 1% (cBioPortal); amplification in 2.2% of KRAS wild-type tumours (Philip 2022). It was among the druggable focal amplifications found at low individual prevalence in 100 whole genomes (Waddell 2015); zenocutuzumab reaches HER2 as the docking arm of its NRG1-blocking mechanism rather than as an amplified driver.","Colorectal cancer: ERBB2 amplification in 2 to 3% of all tumours but 5.3% of RAS and BRAF wild-type ones, which is the population that matters because it overlaps exactly with the patients an EGFR antibody would otherwise be given to (cBioPortal; Richman 2016; 48 of 914 screened for HERACLES). The threshold is the HERACLES criterion, intense membranous staining in more than 50% of cells corresponding to homogeneous amplification, not the 10% used in gastric cancer (Valtorta 2015). HER2 amplification was first proposed as a cause of cetuximab resistance in patient-derived xenografts (Bertotti 2011), and the regimens that followed are trastuzumab plus lapatinib (HERACLES, 30% response), tucatinib plus trastuzumab (MOUNTAINEER) and trastuzumab deruxtecan (DESTINY-CRC02). Plasma HER2 copy number selects patients as well as tissue does (Nakamura 2021). ERBB2 point mutations, 4 to 6%, are mostly passengers in hypermutated tumours and do not qualify.","Gallbladder cancer, amplification versus mutation: ERBB2 alterations were present in 14% of 260 patients, as 8% amplification alone, 4% mutation alone, 1.5% both and 0.4% fusion (Mondaca 2024, MSK-IMPACT), and in 15% of 376 Indian patients with about 8% amplification and an S310F/Y hotspot (Suryavanshi 2025). Only the amplified tumours are seen by IHC and ISH, which is what the zanidatamab label tests for (IHC 3+); the extracellular S310 and kinase-domain mutations need sequencing and are not covered by that label. Protein positivity depends on the scoring rule: 31.3% of 80 resected Japanese gallbladder carcinomas by the gastric guideline (Hiraoka 2020), 12.8% of 187 Chilean cases by breast criteria (Roa 2014), 9.4% of 53 by HERIZON-BTC-01 criteria (Angerilli 2026). ERBB2-driven biliary tumours can lose ERBB2 at progression (Cowzer 2026).","Lung cancer: a mutation target rather than an amplification target, the opposite of breast and stomach cancer. Exon 20 insertions are 1.9 to 2.2% of adenocarcinomas and 3.4% of never-smoker cases, with Y772_A775dup the dominant allele; any ERBB2 mutation reaches about 4%, and amplification, 1 to 3%, is a separate event that the licensed oral inhibitors do not select on (cBioPortal; Kris 2014). Amplification also appears as acquired resistance to EGFR blockade, in 3 of 24 rebiopsied patients (Yu 2013). Immunohistochemistry has no selective role here."],"symbol":"ERBB2","role":[],"sources":[],"specificity":"tumour-associated","distribution":"many-types","tumourAgnostic":true,"specificityNote":"Tumour-associated overexpression or amplification: 7 of 8 label readouts filed under it score protein level or gene copies (HER2 IHC 0 (HER2-negative, including ultralow), HER2 IHC 1+, HER2 IHC 2+ (equivocal, reflex to ISH), HER2 IHC 3+ (HER2-positive by immunohistochemistry) and more), so the medicines rely on the tumour carrying more of it than normal tissue; 1 measure a variant (HER2 (ERBB2) activating mutation). HPA ERBB2: RNA low tissue specificity; blood lineage group enriched (granulocytes 1 nTPM, T-cells 5 nTPM); no normal tissue stained high; highest cancer staining breast cancer (4 of 11 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Gastric & gastro-oesophageal junction cancer, Lung cancer (all types), Biliary tract cancer (all types), Colorectal cancer); approvals of single-target medicines aimed at it also list Bladder & urothelial cancer, Salivary gland cancers, Endometrial cancer, Oesophageal cancer and more, not counted; Open Targets associates it with 15 specific cancer types at or above 0.5 (non-small cell lung carcinoma, gastric cancer, breast carcinoma, gastric adenocarcinoma, urinary bladder cancer, lung adenocarcinoma and more). Tissue-agnostic: HER2 IHC 3+ (HER2-positive by immunohistochemistry) threshold \"IHC 3+\" for Trastuzumab deruxtecan is tissue-agnostic; Trastuzumab deruxtecan US 2024: \"HER2 IHC3+ solid tumours (tumour-agnostic)\". (Rule 3 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"HER2 IHC 0 (HER2-negative, including ultralow) label threshold","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e67e73e-ddf4-4e4d-8b50-09d7514910b6","note":"IHC 0 with membrane staining (ultralow), HR-positive"},{"label":"Human Protein Atlas ERBB2 tissue","url":"https://www.proteinatlas.org/ENSG00000141736-ERBB2/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas ERBB2 pathology","url":"https://www.proteinatlas.org/ENSG00000141736-ERBB2/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000141736 associations","url":"https://platform.opentargets.org/target/ENSG00000141736/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3430","ensembl":"ENSG00000141736","uniprot":"P04626","entrez":"2064","firstDescribed":1985,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Coussens et al, Science, 1985, \"Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2999974/","biology":"Ligand-less receptor that heterodimerises with HER3/EGFR to drive PI3K and MAPK signalling. Amplification is a true oncogenic driver; low expression is merely a delivery address for ADCs.","whereFound":["HER2+ breast cancer (~15-20%)","HER2-low breast cancer (~50%)","Gastric/GEJ (~15-20%)","HER2-mutant NSCLC (~2-3%)","Colorectal (~3-5%)","Biliary tract","Triple-negative breast cancer: her2-low (ihc 1+ or 2+/ish-negative) 24-37%","Triple-negative breast cancer: her2-ultralow (ihc 0 with faint membrane staining in 10% or fewer cells) about 38%","Pancreatic ductal adenocarcinoma: amplification (mutation in a further 1%) 1-5%","Colorectal cancer: high-level amplification 2-3%","Colorectal cancer: activating mutation (not amplification) 4-6%","Gallbladder cancer: amplification 8-10%","Gallbladder cancer: activating mutation (s310f/y hotspot) 4-8%","Gallbladder cancer: protein overexpression (ihc) 9-31%","Non-small-cell lung cancer: exon 20 insertion and kinase-domain missense 2-4%","Non-small-cell lung cancer: high-level amplification 1-3%"],"targetClass":"surface-antigen","prevalence":[{"cancerId":"breast-her2-positive","pct":100,"measure":"IHC 3+ or ISH-amplified (defining)","source":"https://www.nature.com/articles/s41591-025-03981-4"},{"cancerId":"breast-hr-positive","pct":"55-65","measure":"HER2-low (IHC 1+ or 2+/ISH-)","source":"https://www.nature.com/articles/s41591-025-03981-4"},{"cancerId":"tnbc","pct":"30-40","measure":"HER2-low (IHC 1+ or 2+/ISH-)","source":"https://www.nature.com/articles/s41591-025-03981-4"},{"cancerId":"gastric","pct":"15-20","measure":"IHC 3+ or 2+/ISH+","source":"https://en.wikipedia.org/wiki/Trastuzumab","note":"ToGA screening"},{"cancerId":"nsclc","pct":"2-3","measure":"ERBB2 exon 20 mutation","source":"https://www.cbioportal.org/study/summary?id=luad_tcga_pan_can_atlas_2018"},{"cancerId":"colorectal","pct":"3-5","measure":"Amplification/IHC 3+","source":"https://en.wikipedia.org/wiki/HER2/neu","note":"RAS wild-type enriched"},{"cancerId":"cholangiocarcinoma","pct":"10-20","measure":"IHC 3+ or amplification","source":"https://en.wikipedia.org/wiki/HER2/neu","note":"Higher in gallbladder/extrahepatic"},{"cancerId":"tnbc","pct":"24-37","measure":"HER2-low (IHC 1+ or 2+/ISH-negative)","source":"https://doi.org/10.1038/s41523-020-00208-2","note":"36.6% of triple-negative against 65.4% of hormone receptor-positive disease among 3,689 HER2-negative patients (Schettini 2021); 395 of 1,162 hormone receptor-negative tumours, 34.0%, in four German neoadjuvant trials (Denkert 2021); 24.0% of 367 chemotherapy-naive non-metastatic TNBCs (Boissiere-Michot 2026); 63 of 557 DESTINY-Breast04 patients, 11.3%, were hormone receptor-negative (Modi 2022). cBioPortal: IHC 1+ or 2+ recorded for 34 of 166 scored triple-negative samples, 20%, with a further 66 recorded as 0 to 1+ (breast_msk_2018); ERBB2 mutation in 10 of 299, 3.3%, in brca_metabric."},{"cancerId":"tnbc","pct":38,"measure":"HER2-ultralow (IHC 0 with faint membrane staining in 10% or fewer cells)","source":"https://doi.org/10.1007/s00428-026-04425-1","note":"37.6% ultralow, 38.4% null and 24.0% low among 367 non-metastatic TNBCs; ultralow tumours were smaller and lower grade and more often carried BRCA1 promoter methylation, and HER2 category did not affect relapse-free survival over 10.3 years (Boissiere-Michot 2026)."},{"cancerId":"pancreatic","pct":"1-5","measure":"Amplification (mutation in a further 1%)","source":"https://www.cbioportal.org/study/summary?id=paad_tcga_pan_can_atlas_2018","note":"cBioPortal high-level amplification: 9 of 183, 4.9%, in paad_tcga_pan_can_atlas_2018; 12 of 109, 11.0%, in paad_utsw_2015; 28 of 2,336, 1.2%, plus 18 mutations in pdac_msk_2024; 4 of 395 in pancreas_msk_2024. Focal amplifications of ERBB2, MET, FGFR1, CDK6, PIK3R3 and PIK3CA were found at low individual prevalence in 100 whole genomes (Waddell 2015); ERBB2 amplification in 2.2% of 266 KRAS wild-type tumours (Philip 2022)."},{"cancerId":"colorectal","pct":"2-3","measure":"High-level amplification","source":"https://www.cbioportal.org/study/summary?id=crc_msk_2026","note":"cBioPortal high-level amplification: 198 of 7,237, 2.7%, in crc_msk_2026; 35 of 1,134, 3.1%, in crc_msk_2017; 47 of 1,516, 3.1%, in crc_eo_2020; 20 of 592, 3.4%, in coadread_tcga_pan_can_atlas_2018; 8 of 257 in coadread_tcga_pub; 32 of 1,015 in crc_sysucc_2022. ERBB2 amplification was among the potentially drug-targetable recurrent copy-number events named in the TCGA analysis (Cancer Genome Atlas Network 2012). Immunohistochemical overexpression was 2.2% of 1,342 stage IV and 1.3% of 1,914 stage II-III patients, with 27 of 28 stage IV overexpressing cases amplified on fluorescence in situ hybridisation (Richman 2016)."},{"cancerId":"colorectal","pct":"4-6","measure":"Activating mutation (not amplification)","source":"https://www.cbioportal.org/study/summary?id=crc_msk_2026","note":"cBioPortal: 378 of 7,237, 5.2%, in crc_msk_2026; 53 of 1,134, 4.7%, in crc_msk_2017; 64 of 1,516, 4.2%, in crc_eo_2020; 20 of 534, 3.7%, in coadread_tcga_pan_can_atlas_2018; 38 of 619, 6.1%, in coadread_dfci_2016. ERBB3 mutations were among the recurrent receptor kinase events of the Genentech exome series (Seshagiri 2012)."},{"cancerId":"gallbladder","pct":"8-10","measure":"Amplification","source":"https://doi.org/10.1200/go.24.00090","note":"8% amplification alone plus 1.5% amplification with a mutation among 260 patients (Mondaca 2024); about 8% of 376 Indian patients (Suryavanshi 2025); high-level amplification in 25 of 244 samples, 10.2%, in cBioPortal gbc_mskcc_2022 and 7 of 103, 6.8%, in gbc_msk_2018. ERBB2 alterations of any kind: 15% (Giraldo 2022), 16% of 85 (Javle 2016), 14% overall and 15% versus 9% in the American and Chilean cohorts (Mondaca 2024)."},{"cancerId":"gallbladder","pct":"4-8","measure":"Activating mutation (S310F/Y hotspot)","source":"https://doi.org/10.1200/go.24.00090","note":"4% mutation alone, 1.5% with amplification and 0.4% fusion among 260 patients (Mondaca 2024); S310F/Y hotspot predominance among Indian ERBB2 alterations (Suryavanshi 2025); mutations in 19 of 244 samples, 7.8%, in cBioPortal gbc_mskcc_2022; 9.4% of 32 exomes in gbc_shanghai_2014."},{"cancerId":"gallbladder","pct":"9-31","measure":"Protein overexpression (IHC)","source":"https://doi.org/10.1016/j.humpath.2020.08.006","note":"31.3% HER2-positive among 80 resected Japanese gallbladder carcinomas scored by the gastro-oesophageal guideline (Hiraoka 2020); 12.8% overexpression among 187 Chilean cases scored by ASCO/CAP breast criteria, with 20% equivocal (Roa 2014); 9.4% of 53 Italian gallbladder carcinomas HER2-positive by HERIZON-BTC-01 criteria (Angerilli 2026)."},{"cancerId":"nsclc","pct":"2-4","measure":"Exon 20 insertion and kinase-domain missense","source":"https://www.cbioportal.org/study/summary?id=luad_mskcc_2023_met_organotropism","note":"cBioPortal, samples with an exon 20 insertion: 58 of 2,653, 2.2%, in luad_mskcc_2023_met_organotropism; 51 of 2,621, 1.9%, in nsclc_ctdx_msk_2022; 20 of 915, 2.2%, in lung_msk_2017; 8 of 232, 3.4%, in lung_nci_2022; 5 of 302, 1.7%, in luad_oncosg_2020. Any ERBB2 mutation reaches 110 of 2,653 (4.1%) and 103 of 2,621 (3.9%). Y772_A775dup is the dominant allele, 42 of 110 records in luad_mskcc_2023_met_organotropism. The Lung Cancer Mutation Consortium found ERBB2 in 19 of 733, 3% (Kris 2014)."},{"cancerId":"nsclc","pct":"1-3","measure":"High-level amplification","source":"https://www.cbioportal.org/study/summary?id=luad_mskcc_2023_met_organotropism","note":"cBioPortal high-level amplification: 51 of 2,422, 2.1%, in luad_mskcc_2023_met_organotropism; 29 of 915, 3.2%, in lung_msk_2017; 33 of 2,621, 1.3%, in nsclc_ctdx_msk_2022; 9 of 511, 1.8%, in luad_tcga_pan_can_atlas_2018; 12 of 487, 2.5%, in lusc_tcga_pan_can_atlas_2018."}]},"route":"/targets/her2/","neighbours":{"biomarker":[{"id":"her2-mutation","kind":"biomarker","name":"HER2 (ERBB2) activating mutation","route":"/biomarkers/her2-mutation/"},{"id":"her2-ihc-0","kind":"biomarker","name":"HER2 IHC 0 (HER2-negative, including ultralow)","route":"/biomarkers/her2-ihc-0/"},{"id":"her2-ihc-1-plus","kind":"biomarker","name":"HER2 IHC 1+","route":"/biomarkers/her2-ihc-1-plus/"},{"id":"her2-ihc-2-plus","kind":"biomarker","name":"HER2 IHC 2+ (equivocal, reflex to ISH)","route":"/biomarkers/her2-ihc-2-plus/"},{"id":"her2-ihc-3-plus","kind":"biomarker","name":"HER2 IHC 3+ (HER2-positive by immunohistochemistry)","route":"/biomarkers/her2-ihc-3-plus/"},{"id":"her2-ish-amplified","kind":"biomarker","name":"HER2 ISH amplified (ERBB2 gene amplification)","route":"/biomarkers/her2-ish-amplified/"},{"id":"her2-low-ihc","kind":"biomarker","name":"HER2-low (IHC 1+ or IHC 2+/ISH-negative)","route":"/biomarkers/her2-low-ihc/"},{"id":"her2-ultralow","kind":"biomarker","name":"HER2-ultralow (IHC 0 with membrane staining)","route":"/biomarkers/her2-ultralow/"},{"id":"nrg1-fusion","kind":"biomarker","name":"NRG1 gene fusion","route":"/biomarkers/nrg1-fusion/"}],"cancer":[{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/"},{"id":"ampullary","kind":"cancer","name":"Ampullary cancer (ampulla of Vater)","route":"/cancers/ampullary/"},{"id":"apocrine-carcinoma-breast","kind":"cancer","name":"Apocrine carcinoma of the breast","route":"/cancers/apocrine-carcinoma-breast/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/"},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/"},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/"},{"id":"gallbladder-adenocarcinoma","kind":"cancer","name":"Gallbladder adenocarcinoma","route":"/cancers/gallbladder-adenocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/"},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/"},{"id":"mucinous-ovarian-cancer","kind":"cancer","name":"Mucinous ovarian cancer","route":"/cancers/mucinous-ovarian-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"oesophageal-adenocarcinoma","kind":"cancer","name":"Oesophageal and junctional adenocarcinoma","route":"/cancers/oesophageal-adenocarcinoma/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"},{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"},{"id":"salivary-duct-carcinoma","kind":"cancer","name":"Salivary duct carcinoma","route":"/cancers/salivary-duct-carcinoma/"},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/"},{"id":"small-bowel","kind":"cancer","name":"Small intestine cancer (small bowel adenocarcinoma)","route":"/cancers/small-bowel/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"},{"id":"uterine-carcinosarcoma","kind":"cancer","name":"Uterine carcinosarcoma","route":"/cancers/uterine-carcinosarcoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"},{"id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/"},{"id":"her2-tyrosine-kinase-inhibitors","kind":"technology","name":"HER2 tyrosine kinase inhibitors","route":"/technologies/her2-tyrosine-kinase-inhibitors/"},{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/"},{"id":"parsortix-ctc-harvest","kind":"technology","name":"Parsortix label-free circulating tumour cell harvest","route":"/technologies/parsortix-ctc-harvest/"},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/"}],"drug":[{"id":"a166","kind":"drug","name":"A166","route":"/drugs/a166/"},{"id":"absk061","kind":"drug","name":"ABSK061","route":"/drugs/absk061/"},{"id":"afatinib","kind":"drug","name":"Afatinib","route":"/drugs/afatinib/"},{"id":"arx788","kind":"drug","name":"ARX788","route":"/drugs/arx788/"},{"id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/"},{"id":"cinrebafusp-alfa","kind":"drug","name":"Cinrebafusp alfa","route":"/drugs/cinrebafusp-alfa/"},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/"},{"id":"glsi-100","kind":"drug","name":"GLSI-100","route":"/drugs/glsi-100/"},{"id":"gq1005","kind":"drug","name":"GQ1005","route":"/drugs/gq1005/"},{"id":"her2-testing-assays","kind":"drug","name":"HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)","route":"/drugs/her2-testing-assays/"},{"id":"hlx11","kind":"drug","name":"HLX11","route":"/drugs/hlx11/"},{"id":"hlx22","kind":"drug","name":"HLX22","route":"/drugs/hlx22/"},{"id":"iah0968","kind":"drug","name":"IAH0968","route":"/drugs/iah0968/"},{"id":"ibi354","kind":"drug","name":"IBI354","route":"/drugs/ibi354/"},{"id":"inetetamab","kind":"drug","name":"Inetetamab","route":"/drugs/inetetamab/"},{"id":"kn026","kind":"drug","name":"KN026","route":"/drugs/kn026/"},{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/"},{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/"},{"id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/"},{"id":"ose2101","kind":"drug","name":"OSE2101","route":"/drugs/ose2101/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"poziotinib","kind":"drug","name":"Poziotinib","route":"/drugs/poziotinib/"},{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/"},{"id":"ro7771950","kind":"drug","name":"RO7771950","route":"/drugs/ro7771950/"},{"id":"rph-051","kind":"drug","name":"RPH-051","route":"/drugs/rph-051/"},{"id":"sevabertinib","kind":"drug","name":"Sevabertinib","route":"/drugs/sevabertinib/"},{"id":"ssgj-612","kind":"drug","name":"SSGJ-612","route":"/drugs/ssgj-612/"},{"id":"ssgj-705","kind":"drug","name":"SSGJ-705","route":"/drugs/ssgj-705/"},{"id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/"},{"id":"tqb2930","kind":"drug","name":"TQB2930","route":"/drugs/tqb2930/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-biosimilars","kind":"drug","name":"Trastuzumab biosimilars","route":"/drugs/trastuzumab-biosimilars/"},{"id":"trastuzumab-brengitecan","kind":"drug","name":"Trastuzumab brengitecan","route":"/drugs/trastuzumab-brengitecan/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"trastuzumab-duocarmazine","kind":"drug","name":"Trastuzumab duocarmazine","route":"/drugs/trastuzumab-duocarmazine/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"},{"id":"trastuzumab-pamirtecan","kind":"drug","name":"Trastuzumab pamirtecan","route":"/drugs/trastuzumab-pamirtecan/"},{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/"},{"id":"varlitinib","kind":"drug","name":"Varlitinib","route":"/drugs/varlitinib/"},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/"},{"id":"zanidatamab-zovodotin","kind":"drug","name":"Zanidatamab zovodotin","route":"/drugs/zanidatamab-zovodotin/"},{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/"},{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/"}],"company":[{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/"},{"id":"ambrx","kind":"company","name":"Ambrx","route":"/companies/ambrx/"},{"id":"amunix-pharmaceuticals","kind":"company","name":"Amunix Pharmaceuticals","route":"/companies/amunix-pharmaceuticals/"},{"id":"biocon-biologics","kind":"company","name":"Biocon Biologics","route":"/companies/biocon-biologics/"},{"id":"callio-therapeutics","kind":"company","name":"Callio Therapeutics","route":"/companies/callio-therapeutics/"},{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/"},{"id":"dantari","kind":"company","name":"Dantari","route":"/companies/dantari/"},{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/"},{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","route":"/companies/enliven-therapeutics/"},{"id":"galena-biopharma","kind":"company","name":"Galena Biopharma","route":"/companies/galena-biopharma/"},{"id":"glenmark","kind":"company","name":"Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)","route":"/companies/glenmark/"},{"id":"iambic-therapeutics","kind":"company","name":"Iambic Therapeutics","route":"/companies/iambic-therapeutics/"},{"id":"ibex-medical-analytics","kind":"company","name":"Ibex Medical Analytics","route":"/companies/ibex-medical-analytics/"},{"id":"iksuda-therapeutics","kind":"company","name":"Iksuda Therapeutics","route":"/companies/iksuda-therapeutics/"},{"id":"imagene-ai","kind":"company","name":"Imagene AI","route":"/companies/imagene-ai/"},{"id":"myricx-bio","kind":"company","name":"Myricx Bio","route":"/companies/myricx-bio/"},{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/"},{"id":"precirix","kind":"company","name":"Precirix","route":"/companies/precirix/"}],"pathway":[{"id":"bladder-cancer-signalling","kind":"pathway","name":"Bladder cancer (KEGG map)","route":"/pathways/bladder-cancer-signalling/"},{"id":"breast-cancer-signalling","kind":"pathway","name":"Breast cancer (KEGG map)","route":"/pathways/breast-cancer-signalling/"},{"id":"colorectal-cancer-signalling","kind":"pathway","name":"Colorectal cancer (KEGG map)","route":"/pathways/colorectal-cancer-signalling/"},{"id":"dna-replication-licensing","kind":"pathway","name":"DNA replication & origin licensing","route":"/pathways/dna-replication-licensing/"},{"id":"oncogene-activation-two-hit","kind":"pathway","name":"Drivers, passengers & the two-hit model","route":"/pathways/oncogene-activation-two-hit/"},{"id":"drug-efflux-pumps","kind":"pathway","name":"Drug efflux pumps (ABC transporters)","route":"/pathways/drug-efflux-pumps/"},{"id":"endometrial-cancer-signalling","kind":"pathway","name":"Endometrial cancer (KEGG map)","route":"/pathways/endometrial-cancer-signalling/"},{"id":"gastric-cancer-signalling","kind":"pathway","name":"Gastric cancer (KEGG map)","route":"/pathways/gastric-cancer-signalling/"},{"id":"mitotic-spindle-checkpoint","kind":"pathway","name":"Mitosis & the spindle assembly checkpoint","route":"/pathways/mitotic-spindle-checkpoint/"},{"id":"nk-cell-recognition","kind":"pathway","name":"NK-cell recognition: missing self & stress ligands","route":"/pathways/nk-cell-recognition/"},{"id":"organ-tropism-seed-soil","kind":"pathway","name":"Organ tropism: seed and soil","route":"/pathways/organ-tropism-seed-soil/"},{"id":"pancreatic-cancer-signalling","kind":"pathway","name":"Pancreatic cancer (KEGG map)","route":"/pathways/pancreatic-cancer-signalling/"},{"id":"pi3k-akt-mtor","kind":"pathway","name":"PI3K / AKT / mTOR","route":"/pathways/pi3k-akt-mtor/"},{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/"},{"id":"rtk-activation","kind":"pathway","name":"Receptor tyrosine kinase activation","route":"/pathways/rtk-activation/"},{"id":"blood-brain-barrier-metastasis","kind":"pathway","name":"The blood-brain barrier & brain metastasis","route":"/pathways/blood-brain-barrier-metastasis/"}],"term":[{"id":"amplification","kind":"term","name":"Amplification","route":"/terms/amplification/"},{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/"},{"id":"co-amplification","kind":"term","name":"Co-amplification and the 17q12 HER2 amplicon","route":"/terms/co-amplification/"},{"id":"dual-her2-blockade","kind":"term","name":"Dual HER2 blockade","route":"/terms/dual-her2-blockade/"},{"id":"endometrial-molecular-classes","kind":"term","name":"Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)","route":"/terms/endometrial-molecular-classes/"},{"id":"epitope","kind":"term","name":"Epitope","route":"/terms/epitope/"},{"id":"gene-amplification","kind":"term","name":"Gene amplification and copy-number change","route":"/terms/gene-amplification/"},{"id":"sustaining-proliferative-signaling","kind":"term","name":"Hallmark: sustaining proliferative signalling","route":"/terms/sustaining-proliferative-signaling/"},{"id":"genomic-testing-biliary-uk","kind":"term","name":"HER2 and genomic testing for biliary cancer on the NHS","route":"/terms/genomic-testing-biliary-uk/"},{"id":"her2-testing-in-biliary-cancer","kind":"term","name":"HER2 testing in biliary tract cancer (IHC, ISH and NGS)","route":"/terms/her2-testing-in-biliary-cancer/"},{"id":"her2-low","kind":"term","name":"HER2-low and HER2-ultralow","route":"/terms/her2-low/"},{"id":"her2-low-and-trop2-adc-eligibility-tnbc","kind":"term","name":"HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)","route":"/terms/her2-low-and-trop2-adc-eligibility-tnbc/"},{"id":"her2-positive","kind":"term","name":"HER2-positive (IHC 3+ or ISH-amplified)","route":"/terms/her2-positive/"},{"id":"heracles-criteria","kind":"term","name":"HERACLES criteria (HER2 in bowel cancer)","route":"/terms/heracles-criteria/"},{"id":"hgnc-symbol","kind":"term","name":"HGNC gene symbol","route":"/terms/hgnc-symbol/"},{"id":"biliary-anatomy-subtypes","kind":"term","name":"Intrahepatic, perihilar, distal and gallbladder cancer","route":"/terms/biliary-anatomy-subtypes/"},{"id":"oncogene","kind":"term","name":"Oncogene","route":"/terms/oncogene/"},{"id":"overexpression","kind":"term","name":"Overexpression","route":"/terms/overexpression/"},{"id":"receptor","kind":"term","name":"Receptor","route":"/terms/receptor/"},{"id":"somatic-mutation-theory","kind":"term","name":"Somatic mutation theory of cancer","route":"/terms/somatic-mutation-theory/"}],"trial":[{"id":"nct06616766","kind":"trial","name":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","route":"/trials/nct06616766/"},{"id":"nct06439771","kind":"trial","name":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","route":"/trials/nct06439771/"},{"id":"beamion-lung-1","kind":"trial","name":"Beamion LUNG-1","route":"/trials/beamion-lung-1/"},{"id":"cleopatra","kind":"trial","name":"CLEOPATRA","route":"/trials/cleopatra/"},{"id":"nct05523947","kind":"trial","name":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","route":"/trials/nct05523947/"},{"id":"destiny-crc01","kind":"trial","name":"DESTINY-CRC01","route":"/trials/destiny-crc01/"},{"id":"destiny-crc02","kind":"trial","name":"DESTINY-CRC02","route":"/trials/destiny-crc02/"},{"id":"destiny-gastric04","kind":"trial","name":"DESTINY-Gastric04","route":"/trials/destiny-gastric04/"},{"id":"destiny-lung02","kind":"trial","name":"DESTINY-Lung02","route":"/trials/destiny-lung02/"},{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/"},{"id":"determine-arm04","kind":"trial","name":"DETERMINE arm 04: trastuzumab with pertuzumab in HER2-amplified or mutated rare cancers","route":"/trials/determine-arm04/"},{"id":"nct07467863","kind":"trial","name":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07467863/"},{"id":"nct07510802","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","route":"/trials/nct07510802/"},{"id":"nct07462650","kind":"trial","name":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07462650/"},{"id":"nct07641023","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07641023/"},{"id":"nct07589517","kind":"trial","name":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07589517/"},{"id":"nct06043817","kind":"trial","name":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","route":"/trials/nct06043817/"},{"id":"nct07192432","kind":"trial","name":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","route":"/trials/nct07192432/"},{"id":"nct06369831","kind":"trial","name":"HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011","route":"/trials/nct06369831/"},{"id":"her2climb","kind":"trial","name":"HER2CLIMB","route":"/trials/her2climb/"},{"id":"hera-b31-n9831","kind":"trial","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/"},{"id":"herizon-btc-01","kind":"trial","name":"HERIZON-BTC-01","route":"/trials/herizon-btc-01/"},{"id":"herizon-btc-302","kind":"trial","name":"HERIZON-BTC-302","route":"/trials/herizon-btc-302/"},{"id":"herizon-gea-01","kind":"trial","name":"HERIZON-GEA-01","route":"/trials/herizon-gea-01/"},{"id":"kristine","kind":"trial","name":"KRISTINE","route":"/trials/kristine/"},{"id":"mountaineer","kind":"trial","name":"MOUNTAINEER","route":"/trials/mountaineer/"},{"id":"mountaineer-03","kind":"trial","name":"MOUNTAINEER-03","route":"/trials/mountaineer-03/"},{"id":"nct05532696","kind":"trial","name":"Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","route":"/trials/nct05532696/"},{"id":"safir-abc10","kind":"trial","name":"SAFIR-ABC10","route":"/trials/safir-abc10/"},{"id":"soho-01","kind":"trial","name":"SOHO-01","route":"/trials/soho-01/"},{"id":"nct05771584","kind":"trial","name":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","route":"/trials/nct05771584/"},{"id":"toga","kind":"trial","name":"ToGA","route":"/trials/toga/"},{"id":"train-2","kind":"trial","name":"TRAIN-2","route":"/trials/train-2/"},{"id":"trap-btc","kind":"trial","name":"TRAP-BTC","route":"/trials/trap-btc/"},{"id":"treetopp","kind":"trial","name":"TreeTopp","route":"/trials/treetopp/"},{"id":"triumph","kind":"trial","name":"TRIUMPH","route":"/trials/triumph/"}],"paper":[{"id":"paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011","kind":"paper","name":"A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","route":"/key-papers/paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011/"},{"id":"paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013","kind":"paper","name":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","route":"/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/"},{"id":"paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015","kind":"paper","name":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","route":"/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/"},{"id":"paper-javle-biliary-ngs-cancer-2016","kind":"paper","name":"Biliary cancer: utility of next-generation sequencing for clinical management","route":"/key-papers/paper-javle-biliary-ngs-cancer-2016/"},{"id":"paper-fernandez-cuesta-cd74-nrg1-fusion-lung-cancer-discov-2014","kind":"paper","name":"CD74-NRG1 fusions in lung adenocarcinoma","route":"/key-papers/paper-fernandez-cuesta-cd74-nrg1-fusion-lung-cancer-discov-2014/"},{"id":"paper-mody-biliary-ctdna-profiling-jco-po-2019","kind":"paper","name":"Circulating tumor DNA profiling of advanced biliary tract cancers","route":"/key-papers/paper-mody-biliary-ctdna-profiling-jco-po-2019/"},{"id":"paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021","kind":"paper","name":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial (TRIUMPH)","route":"/key-papers/paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021/"},{"id":"paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024","kind":"paper","name":"Clinical and genomic characterization of ERBB2-altered gallbladder cancer: exploring differences between an American and a Chilean cohort","route":"/key-papers/paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024/"},{"id":"paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021","kind":"paper","name":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","route":"/key-papers/paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021/"},{"id":"paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019","kind":"paper","name":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","route":"/key-papers/paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019/"},{"id":"paper-schettini-her2-low-features-npj-breast-cancer-2021","kind":"paper","name":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","route":"/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/"},{"id":"paper-giraldo-gallbladder-msk-impact-ccr-2022","kind":"paper","name":"Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention","route":"/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/"},{"id":"paper-tcga-colorectal-comprehensive-characterization-nature-2012","kind":"paper","name":"Comprehensive molecular characterization of human colon and rectal cancer","route":"/key-papers/paper-tcga-colorectal-comprehensive-characterization-nature-2012/"},{"id":"paper-tcga-lung-adenocarcinoma-nature-2014","kind":"paper","name":"Comprehensive molecular profiling of lung adenocarcinoma","route":"/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/"},{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/"},{"id":"paper-destiny-breast04-nejm-2022","kind":"paper","name":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","route":"/key-papers/paper-destiny-breast04-nejm-2022/"},{"id":"paper-destiny-breast06-nejm-2024","kind":"paper","name":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","route":"/key-papers/paper-destiny-breast06-nejm-2024/"},{"id":"paper-hiraoka-her2-status-biliary-hum-pathol-2020","kind":"paper","name":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer","route":"/key-papers/paper-hiraoka-her2-status-biliary-hum-pathol-2020/"},{"id":"paper-jonna-nrg1-fusions-solid-tumours-ccr-2019","kind":"paper","name":"Detection of NRG1 gene fusions in solid tumors","route":"/key-papers/paper-jonna-nrg1-fusions-solid-tumours-ccr-2019/"},{"id":"paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014","kind":"paper","name":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","route":"/key-papers/paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014/"},{"id":"paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","kind":"paper","name":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)","route":"/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/"},{"id":"paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026","kind":"paper","name":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02","route":"/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/"},{"id":"paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025","kind":"paper","name":"eNRGy: efficacy of zenocutuzumab in NRG1 fusion-positive cancer","route":"/key-papers/paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025/"},{"id":"paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026","kind":"paper","name":"Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-null to HER2-low, including HER2-ultralow status","route":"/key-papers/paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026/"},{"id":"paper-zhang-lung-cancer-never-smokers-nat-genet-2021","kind":"paper","name":"Genomic and evolutionary classification of lung cancer in never smokers","route":"/key-papers/paper-zhang-lung-cancer-never-smokers-nat-genet-2021/"},{"id":"paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019","kind":"paper","name":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","route":"/key-papers/paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019/"},{"id":"paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020","kind":"paper","name":"Genomic landscape of lung adenocarcinoma in East Asians","route":"/key-papers/paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020/"},{"id":"paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025","kind":"paper","name":"Genomic profiling of Indian gallbladder carcinoma: mutational insights in a high-incidence population","route":"/key-papers/paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025/"},{"id":"paper-nakamura-biliary-genomic-spectra-nat-genet-2015","kind":"paper","name":"Genomic spectra of biliary tract cancer","route":"/key-papers/paper-nakamura-biliary-genomic-spectra-nat-genet-2015/"},{"id":"paper-garate-calderon-gallbladder-cancer-worldwide-exome-ebiomedicine-2026","kind":"paper","name":"Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis","route":"/key-papers/paper-garate-calderon-gallbladder-cancer-worldwide-exome-ebiomedicine-2026/"},{"id":"paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016","kind":"paper","name":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials","route":"/key-papers/paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016/"},{"id":"paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026","kind":"paper","name":"HER2 status in extrahepatic cholangiocarcinoma and gallbladder carcinoma: concordance between immunohistochemistry and chromogenic in situ hybridization in 140 cases","route":"/key-papers/paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026/"},{"id":"paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017","kind":"paper","name":"HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","route":"/key-papers/paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017/"},{"id":"paper-katherine-nejm-2019","kind":"paper","name":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","route":"/key-papers/paper-katherine-nejm-2019/"},{"id":"paper-lemmon-schlessinger-rtk-signalling-cell-2010","kind":"paper","name":"Lemmon and Schlessinger 2010: cell signalling by receptor tyrosine kinases","route":"/key-papers/paper-lemmon-schlessinger-rtk-signalling-cell-2010/"},{"id":"paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026","kind":"paper","name":"Molecular and clinical determinants of targeted therapy treatment in biliary tract cancer","route":"/key-papers/paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026/"},{"id":"paper-philip-kras-wild-type-pancreatic-ccr-2022","kind":"paper","name":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","route":"/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/"},{"id":"paper-weinberg-biliary-profiling-jgo-2019","kind":"paper","name":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","route":"/key-papers/paper-weinberg-biliary-profiling-jgo-2019/"},{"id":"paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","kind":"paper","name":"NILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","route":"/key-papers/paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019/"},{"id":"paper-roa-her2-overexpression-gallbladder-gcr-2014","kind":"paper","name":"Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","route":"/key-papers/paper-roa-her2-overexpression-gallbladder-gcr-2014/"},{"id":"paper-javle-mypathway-her2-biliary-lancet-oncol-2021","kind":"paper","name":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","route":"/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/"},{"id":"paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025","kind":"paper","name":"Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance","route":"/key-papers/paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025/"},{"id":"paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","kind":"paper","name":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","route":"/key-papers/paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017/"},{"id":"paper-seshagiri-rspo-fusions-colon-nature-2012","kind":"paper","name":"Recurrent R-spondin fusions in colon cancer","route":"/key-papers/paper-seshagiri-rspo-fusions-colon-nature-2012/"},{"id":"paper-slamon-her2-amplification-science-1987","kind":"paper","name":"Slamon 1987: HER2 gene amplification marks an aggressive form of breast cancer","route":"/key-papers/paper-slamon-her2-amplification-science-1987/"},{"id":"paper-slamon-her2-breast-ovarian-science-1989","kind":"paper","name":"Slamon 1989: HER2/neu in human breast and ovarian cancer","route":"/key-papers/paper-slamon-her2-breast-ovarian-science-1989/"},{"id":"paper-slamon-trastuzumab-nejm-2001","kind":"paper","name":"Slamon 2001: adding trastuzumab to chemotherapy for HER2-positive metastatic breast cancer","route":"/key-papers/paper-slamon-trastuzumab-nejm-2001/"},{"id":"paper-erices-chilean-gallbladder-landscape-front-oncol-2025","kind":"paper","name":"The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population","route":"/key-papers/paper-erices-chilean-gallbladder-landscape-front-oncol-2025/"},{"id":"paper-toga-trastuzumab-gastric-lancet-2010","kind":"paper","name":"ToGA (Bang 2010): trastuzumab with chemotherapy for HER2-positive advanced gastric cancer","route":"/key-papers/paper-toga-trastuzumab-gastric-lancet-2010/"},{"id":"paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021","kind":"paper","name":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01)","route":"/key-papers/paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021/"},{"id":"paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024","kind":"paper","name":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","route":"/key-papers/paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024/"},{"id":"paper-destiny-crc02-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","route":"/key-papers/paper-destiny-crc02-lancet-oncol-2024/"},{"id":"paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)","route":"/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/"},{"id":"paper-lindeman-lung-molecular-testing-guideline-jto-2018","kind":"paper","name":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors","route":"/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/"},{"id":"paper-kris-lung-cancer-mutation-consortium-jama-2014","kind":"paper","name":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","route":"/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/"},{"id":"paper-waddell-whole-genomes-pancreatic-nature-2015","kind":"paper","name":"Whole genomes redefine the mutational landscape of pancreatic cancer","route":"/key-papers/paper-waddell-whole-genomes-pancreatic-nature-2015/"},{"id":"paper-li-gallbladder-exome-erbb-nat-genet-2014","kind":"paper","name":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","route":"/key-papers/paper-li-gallbladder-exome-erbb-nat-genet-2014/"},{"id":"paper-yarden-sliwkowski-erbb-network-nrmcb-2001","kind":"paper","name":"Yarden and Sliwkowski 2001: untangling the ErbB signalling network","route":"/key-papers/paper-yarden-sliwkowski-erbb-network-nrmcb-2001/"},{"id":"paper-harding-lancet-oncol","kind":"paper","name":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","route":"/key-papers/paper-harding-lancet-oncol/"}],"pairing":[{"id":"her2-gastric-sequence","kind":"pairing","name":"HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd","route":"/pairings/her2-gastric-sequence/"}],"idea":[{"id":"idea-tnbc-adc-sequencing-trial","kind":"idea","name":"A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer","route":"/ideas/idea-tnbc-adc-sequencing-trial/"},{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/"},{"id":"idea-fund-abbreviated-pathway-me-too-biologics","kind":"idea","name":"An abbreviated approval path for follow-on antibodies within a validated class","route":"/ideas/idea-fund-abbreviated-pathway-me-too-biologics/"},{"id":"idea-biomarker-quadruplet-gastric","kind":"idea","name":"Biomarker-directed first-line quadruplets in gastric cancer","route":"/ideas/idea-biomarker-quadruplet-gastric/"},{"id":"idea-bio2-myeloid-engager-bispecific","kind":"idea","name":"Bispecific antibodies that engage macrophages instead of T cells","route":"/ideas/idea-bio2-myeloid-engager-bispecific/"},{"id":"idea-bio2-intraventricular-car-t","kind":"idea","name":"Deliver CAR-T cells straight into the fluid around the brain","route":"/ideas/idea-bio2-intraventricular-car-t/"},{"id":"idea-dual-payload-first","kind":"idea","name":"Dual-payload ADCs in first line to prevent resistance","route":"/ideas/idea-dual-payload-first/"},{"id":"idea-her2-adc-serous-endometrial","kind":"idea","name":"HER2 ADCs as standard for HER2-positive serous endometrial cancer","route":"/ideas/idea-her2-adc-serous-endometrial/"},{"id":"idea-bio1-antigen-mapping-at-progression","kind":"idea","name":"Re-map the tumour's surface proteins before choosing the next antibody drug","route":"/ideas/idea-bio1-antigen-mapping-at-progression/"},{"id":"idea-gbc-reflex-her2-testing-advanced-biliary","kind":"idea","name":"Reflex HER2 testing of every advanced gallbladder and extrahepatic biliary cancer","route":"/ideas/idea-gbc-reflex-her2-testing-advanced-biliary/"},{"id":"idea-tnbc-her2-ultralow-testing-uptake","kind":"idea","name":"Reflex re-scoring of HER2 0 versus 1+ with digital assistance so every eligible triple-negative patient reaches trastuzumab deruxtecan","route":"/ideas/idea-tnbc-her2-ultralow-testing-uptake/"},{"id":"idea-bio2-transferrin-shuttle-adc","kind":"idea","name":"Use the brain's own transport door to carry antibody drugs across","route":"/ideas/idea-bio2-transferrin-shuttle-adc/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"},{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/"},{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"target":[{"id":"cd137","kind":"target","name":"CD137 (4-1BB, TNFRSF9)","route":"/targets/cd137/"},{"id":"grb7","kind":"target","name":"GRB7","route":"/targets/grb7/"},{"id":"mien1","kind":"target","name":"MIEN1","route":"/targets/mien1/"},{"id":"pgap3","kind":"target","name":"PGAP3","route":"/targets/pgap3/"},{"id":"pnmt","kind":"target","name":"PNMT","route":"/targets/pnmt/"},{"id":"ptk6","kind":"target","name":"PTK6 (BRK)","route":"/targets/ptk6/"},{"id":"stard3","kind":"target","name":"STARD3","route":"/targets/stard3/"}],"institution":[{"id":"georgetown-lombardi","kind":"institution","name":"Georgetown Lombardi Comprehensive Cancer Center","route":"/institutions/georgetown-lombardi/"},{"id":"hospital-del-mar","kind":"institution","name":"Hospital del Mar / Hospital del Mar Research Institute","route":"/institutions/hospital-del-mar/"},{"id":"instituto-alexander-fleming","kind":"institution","name":"Instituto Alexander Fleming","route":"/institutions/instituto-alexander-fleming/"},{"id":"san-raffaele","kind":"institution","name":"IRCCS Ospedale San Raffaele","route":"/institutions/san-raffaele/"},{"id":"candiolo","kind":"institution","name":"Istituto di Candiolo IRCCS (FPO)","route":"/institutions/candiolo/"},{"id":"mayo-clinic-florida","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Florida","route":"/institutions/mayo-clinic-florida/"},{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","route":"/institutions/ncc-hospital-east/"},{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/"},{"id":"mcgill-goodman","kind":"institution","name":"Rosalind and Morris Goodman Cancer Institute, McGill University","route":"/institutions/mcgill-goodman/"},{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/"},{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/"}],"person":[{"id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","route":"/people/barbara-bradfield/"},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/"},{"id":"bob-li","kind":"person","name":"Bob T. Li","route":"/people/bob-li/"},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/"},{"id":"cristina-saura","kind":"person","name":"Cristina Saura","route":"/people/cristina-saura/"},{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/"},{"id":"ma-fei","kind":"person","name":"Fei Ma","route":"/people/ma-fei/"},{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/"},{"id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","route":"/people/giuseppe-curigliano/"},{"id":"helena-earl","kind":"person","name":"Helena Earl","route":"/people/helena-earl/"},{"id":"ian-krop","kind":"person","name":"Ian E. Krop","route":"/people/ian-krop/"},{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","route":"/people/jason-lewis/"},{"id":"javier-cortes","kind":"person","name":"Javier Cortés","route":"/people/javier-cortes/"},{"id":"lee-jeeyun","kind":"person","name":"Jeeyun Lee","route":"/people/lee-jeeyun/"},{"id":"joaquin-arribas","kind":"person","name":"Joaquín Arribas","route":"/people/joaquin-arribas/"},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/"},{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/"},{"id":"goto-koichi","kind":"person","name":"Koichi Goto","route":"/people/goto-koichi/"},{"id":"nancy-lin","kind":"person","name":"Nancy U. Lin","route":"/people/nancy-lin/"},{"id":"sandra-swain","kind":"person","name":"Sandra M. Swain","route":"/people/sandra-swain/"},{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/"},{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/"},{"id":"shanu-modi","kind":"person","name":"Shanu Modi","route":"/people/shanu-modi/"},{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","route":"/people/kim-sung-bae/"},{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/"},{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/"},{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/"},{"id":"yosef-yarden","kind":"person","name":"Yosef Yarden","route":"/people/yosef-yarden/"},{"id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","route":"/people/bang-yung-jue/"}],"bottleneck":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/"}]}}